Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company developing retinal medicines using its proprietary Antibody Biopolymer Conjugate (ABC) platform. Its lead product, Zenkuda (tarcocimab tedromer/KSI-301), is an anti-VEGF therapy with a 20-day ocular half-life that has completed four Phase 3 studies in diabetic retinopathy, retinal vein occlusion, and wet AMD. Kodiak also develops KSI-501 (anti-IL-6/VEGF bispecific) and KSI-101 (IL-6/VEGF bispecific for macular inflammation), and operates its own commercial-scale manufacturing facility called Ursus.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134887 | EDGAR | 81K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046098 | EDGAR | 82K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038025 | EDGAR | 81K words |
| 2023-03-28 | 2022-12-31 | 0000950170-23-010314 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002555 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009946 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011186 | EDGAR | — |
| 2019-03-27 | 2018-12-31 | 0001564590-19-009601 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-349251 | EDGAR | 54K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-280183 | EDGAR | 54K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108033 | EDGAR | 53K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071523 | EDGAR | 52K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127059 | EDGAR | 50K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097010 | EDGAR | 50K words |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060483 | EDGAR | 49K words |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063767 | EDGAR | 52K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042479 | EDGAR | 51K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022203 | EDGAR | 51K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023870 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016151 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-28 | 0001193125-26-403481 | EDGAR | — |
| 2026-08-13 | 0001193125-26-349107 | EDGAR | 3K words |
| 2026-03-31 | 0001193125-26-134854 | EDGAR | 4K words |
| 2026-03-27 | 0001193125-26-127041 | EDGAR | 4K words |
| 2025-12-18 | 0001193125-25-324882 | EDGAR | 21K words |
| 2025-11-13 | 0001193125-25-280125 | EDGAR | 4K words |
| 2025-08-13 | 0000950170-25-107982 | EDGAR | 4K words |
| 2025-06-03 | 0001193125-25-134149 | EDGAR | 1K words |
| 2025-05-14 | 0000950170-25-071474 | EDGAR | 3K words |
| 2025-03-27 | 0000950170-25-046067 | EDGAR | 5K words |
113 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001468748 |
| Ticker | KOD |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.kodiak.com |
| Listed | 2018-10-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KOD (~200 tokens, structured JSON with cryptographic provenance)